Metabolomic and Lipidomic Insights into Nonalcoholic Fatty Liver Disease

Nonalcoholic fatty liver disease (NAFLD) encompasses a spectrum from simple steatosis to nonalcoholic steatohepatitis (NASH), fibrosis and cirrhosis. Integrative metabolomic and lipidomic approaches have revealed perturbations in fatty acid oxidation, amino acid catabolism and phospholipid remodelling that underpin disease onset and progression. High‐resolution mass spectrometry has enabled the identification of distinct lipid signatures—such as altered cardiolipins, sphingolipids and glycerophospholipids—that correlate with mitochondrial dysfunction and inflammatory injury. Parallel profiling of aqueous metabolites has uncovered shifts in branched‐chain amino acids and tricarboxylic acid cycle intermediates, pointing to disrupted energy homeostasis and oxidative stress. These molecular fingerprints support noninvasive biomarker discovery for early diagnosis and stratification, while highlighting targetable pathways—ranging from oxalate synthesis and peroxisome proliferator‐activated receptor‐α signalling to enzyme-mediated fatty acid elongation—that offer new avenues for therapeutic intervention.

Research from Nature Portfolio

Recent studies have shown that dysregulated hepatic oxalate production, driven by suppression of alanine-glyoxylate aminotransferase and activation of lactate dehydrogenase A, exacerbates steatohepatitis by inhibiting peroxisome proliferator-activated receptor-α and fatty acid β-oxidation. Hepatocyte-specific restoration of glyoxylate detoxification or pharmacological blockade of oxalate synthesis markedly reduces lipid accumulation, inflammation and fibrotic remodelling. In a complementary investigation, a machine-learning‐guided lipidomic analysis of human liver biopsies defined a 32-lipid signature that discriminates NASH from simple steatosis with perfect sensitivity and specificity. This work identified decreased desaturase activity as a bottleneck in long-chain fatty acid synthesis, implicating the FADS1 enzyme in the accumulation of hepatotoxic lipids and offering a mechanistic link between membrane phospholipid composition and lipoapoptosis in NASH.

Metabolomic and Lipidomic Insights into Nonalcoholic Fatty Liver Disease publication trend

The graph below shows the total number of articles in metabolomic and lipidomic insights into nonalcoholic fatty liver disease across all publications each year (not limited to Nature Index journals).

Technical terms

Metabolomics: Comprehensive analysis of small-molecule metabolites in biological samples.

Lipidomics: Systematic study of cellular lipid species and their interactions.

Nonalcoholic fatty liver disease (NAFLD): A range of liver conditions characterised by excessive fat accumulation in hepatocytes, not due to alcohol consumption.

Nonalcoholic steatohepatitis (NASH): An advanced form of NAFLD featuring inflammation, hepatocyte injury and fibrosis.

Biomarker: A measurable molecular indicator of physiological or pathological processes.

Mass spectrometry: An analytical technique to identify and quantify molecules based on mass-to-charge ratio.

References

1. Mitochondrial dysfunction-related lipid changes occur in nonalcoholic fatty liver disease progression. Journal of Lipid Research (2018).
2. Metabolomic‐based noninvasive serum test to diagnose nonalcoholic steatohepatitis: Results from discovery and validation cohorts. Hepatology Communications (2018).
3. Inhibition of hepatic oxalate overproduction ameliorates metabolic dysfunction-associated steatohepatitis. Nature Metabolism (2024).
4. DT-109 ameliorates nonalcoholic steatohepatitis in nonhuman primates. Cell Metabolism (2023).
5. Lipid Nanoparticle‐Mediated Delivery of CRISPR‐Cas9 Against Rubicon Ameliorates NAFLD by Modulating CD36 Along with Glycerophospholipid Metabolism. Advanced Science (2024).
6. Impaired unsaturated fatty acid elongation alters mitochondrial function and accelerates metabolic dysfunction-associated steatohepatitis progression. Metabolism (2024).